Home›Trial›NCT01511393
NCT01511393ENROLLING BY INVITATION

An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)

Study Summary

This study is conducted in the United States of America (USA). The aim of the study is to monitor the number of annual new adult cases of medullary thyroid carcinoma (MTC) and to establish a registry for these new cases in order to identify any possible increase related to the introduction of liraglutide, exenatide once-weekly, and other GLP-1 receptor agonists into the US market.

Conditions
DiabetesDiabetes Mellitus, Type 2Medullary Thyroid CarcinomaWeight Management
Interventions / Drugs
No treatment given
View on ClinicalTrials.gov ↗
Sponsor
NVO
Novo Nordisk
Diabetes/Obesity
F12/100
Study Details
Enrollment6750 participants
Primary Completion—
Lead SponsorNovo Nordisk A/S
Data Retrieved2026-04-11 02:55:47.366879+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Current status: ENROLLING BY INVITATION.

Enrolled: 6,750 participants
Sponsor Catalyst Profile

Novo Nordisk (NVO) is the sponsoring company for this trial. BiotechSign currently grades this company F (12/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

NVO Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.